


## Inthera Bioscience raises CHF 10.5 million in series A financing round

31 May 2017 | News

**Inthera Bioscience employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs).**



Inthera Bioscience, a Swiss biopharmaceutical company developing first-in-class targeted small molecule therapies for solid tumors, today announced the closing of a Series A financing of CHF 10.5 million (EUR 9.6 million).

The financing round was led by Merck Ventures, with equal contribution from Aglaia BioMedical Ventures and Novo Seeds and the participation of a private investor. In conjunction with the financing round, Emmanuelle Coutanceau of Novo Seeds and Keno Gutierrez of Merck Ventures have joined the company's Board of Directors.

Inthera Bioscience employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs). The company's drug discovery programs are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors, which are currently in pre-clinical development.

Jasper Bos, Vice President at Merck Ventures and former Chairman of Inthera's Board of Directors said, "Having been able to play an active role in this venture and to support the translation of outstanding science into highly innovative therapeutics, has been deeply satisfying. Inthera's technology has the potential to radically change our perspective on the druggability of intracellular PPIs."

Klaus Schollmeier, Chairman of the Board of Directors said, "I first met Ulrich in 2015 and have been following Inthera ever since. It is fascinating to watch his entrepreneurial spirit driving everyone involved. The continuous progress in Inthera's lead program is very impressive and a reward for the hard effort and dedication of the whole team. It is a great pleasure to join this exciting endeavour and work with such a strong investor syndicate."

Ulrich Kessler, Chief Executive Officer and co-founder of Inthera said, “We are now in a position to complete the pre-clinical development of our lead program against HPV-associated cancers and expand our operations and pipeline. I am very glad about the strong commitment from our investors and look forward to unfolding Inthera’s innovative potential in oncology supported by our experienced new board members.”